Your browser is no longer supported. Please, upgrade your browser.
Voyager Therapeutics, Inc.
Index- P/E8.17 EPS (ttm)1.04 Insider Own14.07% Shs Outstand37.24M Perf Week2.04%
Market Cap313.48M Forward P/E- EPS next Y-2.55 Insider Trans-0.26% Shs Float31.68M Perf Month1.01%
Income40.10M PEG- EPS next Q-0.63 Inst Own74.90% Short Float4.84% Perf Quarter-30.61%
Sales197.30M P/S1.59 EPS this Y55.90% Inst Trans0.01% Short Ratio4.18 Perf Half Y-34.51%
Book/sh4.46 P/B1.91 EPS next Y-431.20% ROA12.90% Target Price14.09 Perf Year-42.02%
Cash/sh5.42 P/C1.57 EPS next 5Y- ROE38.00% 52W Range6.26 - 14.80 Perf YTD18.88%
Dividend- P/FCF- EPS past 5Y-12.10% ROI-51.90% 52W High-42.57% Beta1.12
Dividend %- Quick Ratio5.10 Sales past 5Y- Gross Margin- 52W Low35.78% ATR0.48
Employees185 Current Ratio5.10 Sales Q/Q477.50% Oper. Margin18.90% RSI (14)52.91 Volatility5.27% 6.35%
OptionableYes Debt/Eq0.00 EPS Q/Q656.40% Profit Margin20.30% Rel Volume1.46 Prev Close8.92
ShortableYes LT Debt/Eq0.00 EarningsOct 29 BMO Payout0.00% Avg Volume366.60K Price8.50
Recom2.20 SMA204.15% SMA50-0.77% SMA200-21.76% Volume536,975 Change-4.71%
Dec-24-20Downgrade Cantor Fitzgerald Overweight → Neutral $15 → $10
Dec-23-20Downgrade Raymond James Outperform → Mkt Perform
Nov-11-20Downgrade Oppenheimer Outperform → Perform
Nov-10-20Downgrade Wells Fargo Overweight → Equal Weight $10
Nov-10-20Downgrade Raymond James Strong Buy → Outperform $28 → $17
Mar-19-20Initiated The Benchmark Company Buy $18
Feb-06-20Initiated Oppenheimer Outperform
Nov-15-18Upgrade Raymond James Outperform → Strong Buy
Sep-10-18Resumed BTIG Research Buy $32
Sep-10-18Downgrade Morgan Stanley Overweight → Equal-Weight
Jun-04-18Initiated H.C. Wainwright Buy $30
Mar-12-18Downgrade Wedbush Outperform → Neutral $29
Mar-12-18Downgrade Evercore ISI Outperform → In-line
Feb-02-18Initiated Morgan Stanley Overweight
Nov-28-17Resumed Piper Jaffray Overweight $28
Oct-31-17Initiated Robert W. Baird Outperform $31
Oct-27-17Initiated Canaccord Genuity Buy $35
Oct-23-17Reiterated Stifel Buy $20 → $31
Oct-12-17Initiated Raymond James Outperform $35
Aug-17-17Initiated Evercore ISI Outperform $12
Jan-11-21 04:03PM  
Dec-23-20 08:29AM  
Dec-22-20 04:17PM  
Dec-09-20 09:43PM  
Nov-16-20 09:48AM  
Nov-09-20 05:15PM  
Oct-28-20 12:32PM  
Oct-21-20 08:27PM  
Oct-13-20 09:10AM  
Oct-12-20 04:01PM  
Oct-01-20 04:01PM  
Sep-15-20 04:01PM  
Sep-14-20 04:30PM  
Sep-11-20 03:27PM  
Sep-03-20 04:29PM  
Aug-21-20 10:35AM  
Aug-10-20 08:25AM  
Aug-04-20 08:18AM  
Aug-03-20 04:30PM  
Jul-08-20 08:49AM  
Jun-27-20 01:19PM  
Jun-17-20 04:04PM  
Jun-16-20 04:01PM  
May-12-20 01:40PM  
May-11-20 12:56PM  
May-06-20 07:00AM  
Apr-29-20 07:30AM  
Apr-28-20 12:33PM  
Apr-21-20 05:35AM  
Apr-03-20 08:30AM  
Mar-26-20 01:51AM  
Mar-09-20 08:00AM  
Mar-03-20 05:15PM  
Feb-26-20 05:00PM  
Feb-25-20 04:30PM  
Feb-24-20 08:43AM  
Jan-10-20 10:25AM  
Dec-17-19 06:00AM  
Dec-11-19 10:32AM  
Nov-12-19 09:05PM  
Nov-06-19 07:35AM  
Oct-31-19 08:00AM  
Oct-30-19 04:35PM  
Oct-28-19 04:14PM  
Sep-25-19 08:00AM  
Sep-24-19 09:00AM  
Sep-02-19 01:07AM  
Aug-28-19 08:00AM  
Aug-09-19 09:23PM  
Aug-05-19 04:30PM  
Aug-02-19 06:04AM  
Jul-30-19 04:30PM  
Jul-08-19 10:53AM  
Jun-18-19 10:47AM  
Jun-17-19 07:30AM  
Jun-11-19 04:30PM  
May-30-19 02:36PM  
May-20-19 04:30PM  
May-07-19 08:35AM  
May-05-19 09:05AM  
May-02-19 10:32AM  
Apr-30-19 10:37AM  
Apr-29-19 07:04AM  
Apr-15-19 12:25PM  
Apr-03-19 04:15PM  
Apr-02-19 04:15PM  
Mar-28-19 04:15PM  
Mar-11-19 08:00AM  
Mar-10-19 10:36AM  
Mar-08-19 08:00AM  
Mar-06-19 07:50AM  
Mar-04-19 05:03PM  
Mar-01-19 09:29PM  
Feb-28-19 10:32PM  
Feb-26-19 09:22PM  
Feb-25-19 08:19AM  
Feb-22-19 02:40PM  
Voyager Therapeutics, Inc., a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe neurological diseases. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1b clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyotrophic lateral sclerosis; VY-HTT01 for Huntington's disease; VY-FXN01 for Friedreich's ataxia; Tau program for the treatment of tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia; and alpha-synuclein program for synucleinopathies, Parkinson's disease, Lewy Body Dementia, and multiple system atrophy. The company has strategic collaboration agreements with the University of Massachusetts; and ClearPoint Neuro, Inc., as well as collaborations with Brammer Bio and Fujifilm Diosynth Biotechnologies to support the development of its gene therapy programs. It also has a collaboration and license agreement with Neurocrine Biosciences, Inc. for the research, development, and commercialization of adeno-associated virus-based gene therapy products. Voyager Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Turenne AndrePresident & CEOJan 12Sale8.6210,44390,019156,352Jan 14 05:59 PM
Dorval AllisonChief Financial OfficerJan 12Sale8.622,94225,36049,080Jan 14 05:57 PM
Khwaja OmarSee remarksMay 21Sale12.963,50045,36056,500May 22 06:15 PM
Hesslein Robert W.Senior VP & General CounselApr 03Sale8.513,09126,30452,534Apr 07 05:24 PM
Turenne AndrePresident & CEOJan 21Sale13.3610,705143,01985,545Jan 29 05:26 PM
Ottmer Matthew P.Chief Operating OfficerJan 21Sale13.363,72449,75326,276Jan 29 05:26 PM
Dorval AllisonChief Financial OfficerJan 21Sale13.363,12841,79024,522Jan 29 05:27 PM